PYY and steatosis: Dysbiosis of the gut microbiota is known to affect the production of SCFA, altering the bile acid profile and the endocannabinoid system, causing a reduction in GLP-1, GLP-2 (glucagon-like-peptide 1,2) and PYY (peptide YY), which lead to an impaired gut barrier and pave the way for a cascade of events that lead to decreased insulin sensitivity, increased ongoing inflammation, more oxidative stress, increased steatosis, and increased fat mass [17].